Overview

A Phase I Clinical Trial of SyB L-0501 in Combination With Rituximab to Patients With Aggressive B-cell Non-Hodgkin's Lymphoma

Status:
Completed

Trial end date:
2010-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the safety of SyB L-0501 in combination with Rituximab to patients with aggressive B-cell non-Hodgkin's lymphoma, and to explore the recommended dose for the Phase II clinical trial.

Phase:

Phase 1

Details

Lead Sponsor:

SymBio Pharmaceuticals

Treatments:

Bendamustine Hydrochloride
Rituximab